Odagiri S, Matsunaga K, Suzuki K, Murohashi K, Takahashi H, Numata H, Takahashi K, Yamaki I, Ishii S
Department of Respiratory Disease, Kanagawa Prefectual Nagahama Hospital.
Jpn J Antibiot. 1988 Oct;41(10):1538-44.
Twelve patients with respiratory tract infections were treated with cefpodoxime proxetil (CS-807, CPDX-PR), a new cephem antibiotic. It was given orally at a dose of 200 mg 2 times a day for 4 approximately 15 days. Its clinical effects were evaluated as excellent in 1 case, good in 9 cases and poor in 2 cases. The efficacy rate was 83.3%. Its bacteriological effects were evaluated as eradication in 5 strains and decrement in 1 strain. The eradication rate was 83.3%. No adverse reactions and disorder of laboratory findings due to CPDX-PR were observed.
12例呼吸道感染患者接受了新的头孢烯类抗生素头孢泊肟酯（CS - 807，CPDX - PR）治疗。口服给药，剂量为200mg，每日2次，疗程约4至15天。临床疗效评估为：优1例，良9例，差2例。有效率为83.3%。细菌学疗效评估为：5株菌清除，1株菌减少。清除率为83.3%。未观察到因CPDX - PR引起的不良反应及实验室检查异常。
